To investigate the molecular basis of the phenotypic heterogeneity in congenital erythropoietic porphyria, the mutations in the uroporphyrinogen m synthase gene from unrelated patients were determined. Six missense (L4F, Y19C, V82F, V99A, A104V, and G225S), a nonsense (Q249X), a frameshift (633insA), and two splicing mutations (IVS2+ and IVS9AA+4) were identified. When L4F, Y19C, V82F, V99A, A104V, 633insA, G225S, and Q249X were expressed in Eseherichia cok, only the V82F, V99A, and A104V alleles expressed residual enzymatic activity. Of note, the V82F mutation, which occurs adjacent to the 5' donor site of intron 4, resulted in -54% aberrantly spliced transcripts with exon 4 deleted. Thus, this novel exonic single-base substitution caused two lesions, a missense mutation and an aberrantly spliced transcript. Of the splicing mutations, the IVS2+1 allele produced a single transcript with exon 2 deleted, whereas the IVS9AA+4 allele was alternatively spliced, -26% being normal transcripts and the remainder with exon 9 deleted. The amount of residual activity expressed by each allele provided a basis to correlate genotype with disease severity, thereby permitting genotype/phenotype predictions in this clinically heterogeneous disease. (J. Clin. Invest. 1995. 95:905-912.)
Introduction
Congenital erythropoietic porphyria (CEP),' also known as Gunther disease, is an inborn error of heme biosynthesis resulting from the markedly deficient activity of the fourth en-phyrin I; URO-synthase, uroporphyrinogen [II synthase. zyme of the heme biosynthetic pathway, uroporphyrinogen HI synthase (URO-synthase; EC 4.2.1.75), and the accumulation of the nonphysiologic uroporphyrin I (URO I) isomer (1) (2) (3) . In patients with this autosomal recessive disease, the clinical manifestations are markedly heterogeneous, ranging from nonimmune hydrops fetalis to milder, later onset forms which have only cutaneous lesions in adult life (1, 2, (3) (4) (5) (6) . Severely affected patients are transfusion dependent throughout life, have secondary hypersplenism, and are usually disfigured due to the cutaneous involvement. Additional manifestations may include hypertrichosis, alopecia, and erythrodontia. Although milder patients have some residual activity to synthesize sufficient heme for hematopoiesis and for other essential heme-requiring proteins, the amount of residual activity appears to be correlated with clinical severity (7, 8) .
URO-synthase normally catalyzes the conversion of the linear tetrapyrrole, hydroxymethylbilane, to uroporphyrinogen III, the physiologic cyclic isomer which is metabolized in subsequent enzymatic steps to heme (9, 10) . The markedly deficient activity of URO-synthase results in the nonenzymatic conversion of hydroxymethylbilane to the uroporphyrinogen I isomer, which is then oxidized to the nonphysiologic and pathogenic compound, URO I. Excessive URO I in erythrocytes leads to hemolysis and the released porphyrin isomer is deposited in tissues and bones and is excreted in the urine and feces. Light activates the photocatalytic URO I resulting in tissue damage and the formation of bullous lesions which rupture, often becoming infected, leading to bone resorption and cutaneous deformity (11 -14) .
Human URO-synthase has been purified to homogeneity from erythrocytes and shown to be a monomeric protein with an apparent molecular mass of 29.5 kD (15) . Recently, the fulllength cDNA encoding the human URO-synthase polypeptide of 265 amino acids was isolated, sequenced, and expressed in Escherichia coli (16) . Using the cDNA as a probe, a single URO-synthase gene was assigned to the narrow chromosomal region, lOq25.3 -+ q26.3 (17) . Analysis of the URO-synthase genomic sequence revealed 10 exons, and the sequence of each exon-intron junction has been determined (7) . The availability of the URO-synthase cDNA permitted investigation of the molecular lesions causing CEP. To date, six missense mutations (7, 8, (18) (19) (20) , an 80-bp insertion, and a 98-bp deletion (dell48-245) (20) have been identified in unrelated CEP patients. Of note, only the C73R lesion was common, occurring in about one third of the CEP alleles studied, whereas the other mutations were detected only in one to three unrelated families (7, 8, (18) (19) (20) . Each of the missense mutations has been expressed in E. coli (8, 20) , and several were found to have significant residual activity which appeared to correlate with milder phenotypes (7, 8, 20 (25) , the strands were denatured in 10 yl of 0.1 M NaOH for 30 min, and the nonbiotinylated strands were eluted with two 50-sl washes of 0.1 M NaOH. The biotinylated strands were washed with 50 MI of the binding and washing buffer (10 mM Tris-HCl, pH 7.5, containing 1.0 mM EDTA and 2.0 M NaCl) and then with 50 p1 of Tris-EDTA buffer. The biotinylated strands were resuspended in 7 MI of H20 and used as templates for dideoxy chain sequencing (26) . The sequencing gels were loaded with the C (and then T, A, and G) reactions from a series of patients in adjacent wells so that the nucleotide sequence could be rapidly read by pattern recognition and mutations could be easily identified (see Fig. 1 ).
Prokaryotic expression and characterization of URO-synthase mutations. The normal and mutant URO-synthase alleles were expressed in E. coli using the pKK223-3 vector (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ) as previously described (8, 16) . pKK-UROS-V99A, pKK-UROS-A104V, pKK-UROS-633insA, and pKK-UROS-G225S were constructed by cassette substitution of the cloned mutant cDNA into the pKK-UROS vector (8) , while the pKK-UROS-L4F, pKK-UROS-Y19C, pKK-UROS-V82F, pKK-UROS-Q249X constructs were engineered by mega-primer PCR mutagenesis (27), and then were cassette-substituted into the pKK-UROS vector.
For construction of pKK-UROS-V99A, sense primer CW153 corresponding to nucleotide (nt) 385-294 of the URO-synthase cDNA with the underlined T to C transition at nt 296 (5 '-tatattctgcaagcttttctgc atttccacaggtttctccttctgtatccaggccaattttactcactagaagcagtagcatttccagcc-3') and antisense primer WXl9 corresponding to nt 73-92 of UROsynthase cDNA (5 '-ttatatggacttgaagccac-3') were used to amplify pKK-UROS. The amplification product was digested with HindIll and the 225-nt Hindill fragment was used as a cassette to replace the corresponding fragment in pKK-UROS. pKK-UROS-AI04V was similarly constructed except that primer CW155, which corresponded to nt 385-310 with the underlined C to T transition at nt 311 (5 '-tatattctgcaagcttttctgcatttccacaggtttctccttctgtatccaggccaattttactcactagagaaac-3'), was used in place of primer CW153. For pKK-UROS-633insA, sense primer CW1 31 (5 '-ggcgcggaattcccggggatccgtcgacctgcagccaagctgtcccgcgagtgccc-3'), which corresponded to 35 bp of the polycloning site of the pKK223-3 vector, the adjacent 15 bp of the URO-synthase cDNA, and an additional 6-bp non-pKK-UROS sequence at its 5' end, was used with antisense primer WXl1 (5 '-aacttaatttgatcgatattgtcaccagattaactcctgaatg-3'), which correspond to nt 642-621 of URO-synthase cDNA and had the underlined insertion of an A after nt 633, was used to amplify pKK-UROS. The amplification product was digested with ClaI and then EcoRI, and the 717-nt fragment was cassette inserted into pKK-UROS. pKK-UROS-G225S was made by replacing the ClalBsu36I fragment with a cassette generated by amplification of pKK-UROS using sense primer WX12, corresponding to nt 628-673 with the underlined G to A transition at nt 673 (5 '-gagttatctggtgacaatatcgatcaaattaagtttgcagccatca-3'), and antisense primer WX18 (5 '-accgcttctgcgttctgatt-3') which annealed to the pKK223-3 vector sequence downstream of the HindIll subcloning site.
The mega-primer procedure (27) was used to engineer the following expression constructs. For pKK-UROS-L4F, the sense primer CW131 and antisense primer CW71 coresponding to nt 381-357 of the UROsynthase cDNA (5'-ttctgcaagcttttctgcatttcca-3') were used to amplify a 422-nt URO-synthase cDNA sequence containing the L4F mutation. The 422-nt PCR product was gel purified and used as a mega-primer to amplify the URO-synthase cDNA with antisense primer WX15, which corresponded to nt 728-701 of the URO-synthase cDNA (5'-gcagtgcagcttacaggaaggccctggg-3'). The final 769-nt PCR product was digested with ClaI and EcoRI, and the resulting 717-nt fragment was cassette inserted into pKK-UROS. For pKK-UROS-Y19C, sense primer CW131 and antisense primer CW163, which corresponded to nt 102-55 with the underlined A to G transition at nt 56 (5 '-agggatcaaagtggcttcaagtccatataatcctaattccctgatac-3'), were used to amplify the URO-synthase cDNA to generate the mega-primer, which was then used to amplify the URO-synthase cDNA with antisense primer WX15. The final PCR product was digested with Clal and EcoRI, and the 717-nt fragment was cassette inserted into pKK-UROS. For pKK-UROS-V82F, the mega-primer was generated by amplification of URO-synthase cDNA with sense primer WX4, which corresponded to nt 222-246 with the underlined G to T transversion at nt 244 (5 '-ggagcagcaaaacaataaaactgaattc-3') and antisense primer CW71. The mega-primer was used with sense primer CW131 to amplify the URO-synthase cDNA, and the 422-nt product was digested with HindIII. The liberated 225-nt fragment was then cassette inserted into pKK-UROS.
For expression, each construct was used to transform of E. coli strain JM109. Single colonies were isolated and the inserts were completely sequenced to confirm the engineered sequence and the absence of PCR errors. Bacterial growth, isopropylthiogalactoside induction, and UROsynthase assays were performed as previously described (8, 16) . For enzyme stability studies, samples from the bacterial lysates, equalized for enzymatic activity, were incubated at 370C in the presence of 0.5 mg/ml of bovine serum albumin (Sigma Chemical Co., St. Louis, MO) for 60 min. Aliquots were removed at timed intervals, placed on ice, and the URO-synthase activity was determined by the coupled assay (16) .
Analysis of splicing mutations. To determine the presence of stable, aberrantly spliced transcripts for the IVS2"', IVS9AA+4, and V82F
alleles, mRNA was isolated from the respective lymphoid cell line using the FastTrackrm mRNA Isolation Kit version 3.6 (Invitrogen, San Diego, CA) and reverse-transcribed with Moloney murine leukemia virus reverse-transcriptase (RT) according to manufacturer's instructions (New England Biolabs, Inc., Beverly, MA), using as primer the antisense oligonucleotide CW129 (5 '-atgcctggctccatccag-3'), which is complementary to nt 866-849 of the URO-synthase cDNA. The 937 bp URO-synthase RT product was then PCR-amplified (24) with sense primer WX169 (5 '-gcagccttttcgctgggactgcgcgacacc-3') and antisense primer WX174 (5 '-atggggccagcgctaggtggctgac-3'), which annealed to nt 114-84 and nt 823-799 of the URO-synthase cDNA, respectively.
The amplification reaction (100 t1) contained 2 p1 of the URO-synthase RT-PCR product, 100 pmol of each primer, 10 nmol of each dNTP, 50 mM Tris-HCl, pH 9.0, 50 mM NaCl, 10 mM MgCl2, and 2 U of Taq polymerase (Promega Biotec). After an initial 5 min incubation at 94°C, amplification (30 cycles) was performed with denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1 min. The RT-PCR products were electrophoresed in 1% low melting point agarose gels. The normal and abnormally sized bands were gel purified using the WizardTM PCR Preps DNA purification system (Promega Biotec) and sequenced with an Exo ( -) Pfu CyclistTm DNA Sequencing Kit (Stratagene, La Jolla, CA), according to the respective manufacturer's instructions. The relative amount of the normally and abnormally spliced transcripts for the IVS2+', IVS9AA+4, and V82F alleles were determined as follows. For the IVS2+'/L4F genotype, the URO-synthase RT-PCR products were amplified using antisense primer WX3 (5 '-caggatgagaaagcttctca-3'), which anneals to nt 141-160 of URO-synthase cDNA, and sense primer WX 173 (5 '-tgccctataaggactgccaggcaataatgaaggtc-3'), which annealed to nt -26-9 of URO-synthase cDNA, and contained the underlined T to C mismatch that created an AvaIl restriction site in the PCR product derived from the normal transcript. The 186-bp PCR product was gel purified as above, digested with AvalI (New England Biolabs, Inc.), and electrophoresced in a 2% agarose gel. For the IVS9AA+4/IVS9AA+4 genotype, the RT-PCR reaction was performed as described above using sense and antisense primers WX169 and WX174, respectively, except that 10 mCi of a-32P-dCTP was added to each amplification reaction. The normal and abnormal bands were individually gel purified, the mean radioactivity of each (normalized for the number of cytosine residues) was determined using a model 1219 RackBeta Liquid Scintillation Counter (Pharmacia LKB Nuclear, Gaithersburg, MD). _ 519-538 of the URO-synthase cDNA, respectively. The radioactive PCR products were purified as above, digested with EcoRI (New England Biolabs, Inc.) which recognizes only the V82F allele, and then electrophoresed in a 1.5% agarose gel. The PCR product and digestion fragments were gel purified, and the radioactivity of each was measured and normalized for the number of adenine residues as above.
Results
Identification of the URO-synthase mutations. Each of the URO-synthase exons and their respective intron/exon junctions were amplified from the genomic DNAs of 20 unrelated CEP patients using biotinylated primers for rapid strand separation and single-strand solid phase sequencing. As shown in Fig. 1 , the individual dideoxy chain sequencing reactions (e.g., C, A, T, of G) for a series of patients were run side by side, permitting rapid identification by deviations from the normal pattern of point mutations (e.g., Fig. 1 , exon 2) as well as small or large insertions and deletions (e.g., Fig. 1, exon 9 ). Using this technique, URO-synthase mutations in each of the 20 unrelated patients were identified ( 32.5 and 10.0%, respectively, of the 40 alleles studied here, and 26.6 and 9.4% of the 64 CEP alleles reported here and elsewhere (7, 8, (18) (19) (20) . Prokaryotic expression of the URO-synthase mutations. To 18-20. further characterize the URO-synthase mutations, pKK-UROS expression vectors for each of the newly identified exonic mutations were constructed, sequenced, and expressed in E. coli. Table IV shows the mean and range of URO-synthase activity for the expressed normal allele and each mutant allele. Only the missense mutations V82F, V99A, and A104V had mean residual activities that were >3% of the expressed mean normal activity. Notably, the V82F allele expressed 35 .8% of that expressed by the normal allele. However, incubation of the expressed activity at 37°C revealed that the V82F activity was Figure 2 . Thermostability of the URO-synthase activity expressed by pKK-UROS, pKK-UROS-V82F, and pKK-UROS-A66V (8) less stable than the normally expressed enzyme, the half-lives being 30 .5 and 49.5 min, respectively (Fig. 2) . The thermostability of the V82F enzyme at 37TC and 60 min was similar to that of the previously reported V66A allele which expressed significant residual activity (15% of normal) in E. coli (8) .
Analysis of the URO-synthase splicing mutations. The putative splicing mutations (IVS2", IVS9'AA+4, and V82F) were characterized by sequencing the URO-synthase RT-PCR products and determining their relative abundance in the respective lymphoid cell lines. Two RT-PCR products were present in the IVS2+'/L4F lymphoid cells, a normal product of 937 bp, and a smaller 848-bp product in which the entire exon 2 was deleted (Fig. 3 A) . That the IVS2+1 allele did not produce any normalsized URO-synthase transcripts was indicated by the absence of detectable Avail digestion fragments. Two URO-synthase RT-PCR products were present in the IVS9 A+4/IVS9AA+4 lymphoid cells, a normal product of 937 bp, and a smaller 838-bp product in which sequencing revealed that the entire exon 9 was deleted (Fig. 3 B) . Radiolabeling of the RT-PCR products from three independent experiments revealed that 73.5% (range 69.0-77.9%) of the IVS9AA+4/IVS9AA+4 RT-PCR products had the exon 9 deletion. Two URO-synthase RT-PCR products were present in L4F/V82F lymphoid cells, a normal product of 937 bp, and a smaller 840-bp product in which sequencing revealed that the entire exon 4 was deleted (Fig. 3 C) . Radiola and/or a recent examination by one of us (R. J. Desnick). Homoallelism for the most common allele, C73R, was associated with nonimmune hydrops fetalis and/or transfusion dependency from birth, as evidenced by the phenotypes of patients 5, 19, and 20 . Heteroallelism of C73R with a mutation that expressed little, if any, residual activity (8 and Table IV ) also resulted in a severe or moderately severe phenotype (e.g., patients 2, 7, and 15). In contrast, patients heteroallelic for mutations that expressed residual activity (e.g., C73/A66V, L4F/ V82F, and T62A/Q249X) were milder, even if one of the alleles expressed no activity (8 Fig. 1 D) . In this way, the entire coding region and all intron/exon boundaries from each patient were rapidly sequenced and any lesions were detected by pattern recognition, rather than by completely reading the nucleotide sequence for each patient. Since all exons and intron/exon boundaries must be sequenced to identify all possible disease-causing mutations in each allele, the direct sequencing strategy provided a single, efficient approach for mutation analysis and sequencing. This direct sequencing strategy proved more rapid and efficient for mutation detection in this large gene containing 10 exons encoding 265 residues than mutation detection methods such as the single strand conformation polymorphism technique (28) , heteroduplex analysis (29) , or the use of denaturing gradient gel electrophoresis (30) , each of which requires one round of mutation detection followed by sequencing (e.g., 20). This amplification and sequencing strategy has proven efficient for mutation analysis in this gene, as well as for others studied in this laboratory (31, 32) .
8 of the 10 new mutations were single base substitutions. Only the G225S lesion occurred at a CpG dinucleotide, a mutational "hot spot" due to deamination of methylcytosine to thymidine (33, 34) . During the course of this investigation, the L4F mutation was reported independently by Boulechfar et al. (20) . Mutations L4F, Y19C, V82F, and G225S markedly altered the nature of the encoded amino acid (e.g., charge, size, etc.), whereas mutations V99A and A104V substituted isofunctional residues. Of note, expression of the missense mutations revealed that those that altered charge, size, or hydrophilicity had no activity, or very low levels of residual activity, whereas isofunctional substitutions had detectable residual activities. Of interest, the V82F lesion expressed -36% of expressed normal activity. However, the V82F residual activity was inactivated in vitro at 37TC at a rate about twice that of the normal expressed enzyme, presumably reflecting the decreased stability of this mutant protein in vivo. The nonsense lesion Q249X predicted premature truncation of the normal 265 amino acid polypeptide, deleting the terminal 17 residues of the enzyme. Expression of this mutation resulted in little, if any, detectable activity. The 633insA frameshift occurred in codon 212 and predicted different amino acids in residues 212 and 213, and premature truncation of the remaining 52 carboxy-terminal amino acids. Expression of the 633insA lesion resulted in very little, if any, activity.
The IVS2+', IVS9AA+4, and V82F mutations all involved the 5' donor splice consensus sequence, G/gtaag (35, 36) . The IVS2 +' lesion occurred at invariant position 1 of intron 2, a mutation that typically results in exon skipping (37) . Analysis of the RT-PCR products from the IVS2+1/L4F patient by AvaII digestion (which would only cleave the normal sequence) did not digest any normally sized transcripts, indicating that all the transcripts encoded by the IVS2 ' allele were aberrant (Fig. 3  A) . In contrast, the adenine deletion in the +3 or +4 position of the intron 9 consensus sequence resulted in two URO-synthase transcripts (Fig. 3 B) . The shorter, exon 9 deleted transcript represented -73.5% of the radiolabeled RT-PCR products encoded by this allele. Thus, the IVS2 +' allele expressed no functional enzyme, whereas the IVS9 A+4 allele produced -25% normal transcripts encoding the active enzyme monomer. Of note, the V82F mutation, which substituted a C to G in the most 3' nucleotide of exon 4, altered the 5' splice consensus sequence and resulted in abnormal splicing in -54% of the transcripts encoded by this allele. Thus, the V82F single base substitution resulted in two lesions, about half the transcripts were aberrantly spliced, while the remainder encoded a missense mutation which had -35% of normal activity (albeit thermolabile) when expressed in E. coli. A similar exonic lesion which caused alternative splicing of the aS5(IV) collagen gene was previously identified in a patient with Alport syndrome (38) .
The identification of these mutations further expands the molecular heterogeneity of the URO-synthase mutations causing CEP. To date, a total of 14 different mutations has been identified in studies of 32 unrelated CEP patients. The C73R mutation was the most common CEP allele, occurring in 26.6% of all CEP alleles studied (7, 8, (18) (19) (20) . The L4F allele also was common, occurring in -10% of all CEP patients studied. Expression of these mutations in E. coli provided the opportunity to correlate genotype, predicted residual activity, and disease severity. Of the 20 patients studied, both alleles were identified in 14, permitting initial genotype/phenotype correlations. The three CEP patients who were homoallelic for C73R were severely affected, having hydrops fetalis and requiring intrauterine transfusions (patient 20), being stillborn (patient 19), or transfusion dependent, expiring at 5 mo (patient 5). The clinical phenotypes of these three patients suggest that homoallelism for C73R produces insufficient activity to sustain life, consistent with the fact that the C73R mutation had little, if any, activity when expressed in E. coli. (8, 20) . In contrast, homoallelism for the IVS9aA+4 mutation resulted in a mild phenotype, since -25% of the transcripts encoded by this allele were normal. As no other patients were homoallelic for their lesions, the respective phenotype depends on the amount of residual activity contributed by each mutant allele. Since the C73R mutation encodes negligible activity, the four patients heteroallelic for C73R provide information on the effects of the L4F, A66V, A104V, and T228M alleles. The C73R/L4F patient was not transfusion dependent, but was moderately severe, consistent with the fact that the L4F allele expressed relatively little residual activity in E. coli (Table IV) . In contrast, the patients heteroallelic for the A66V, A104V, and T228M alleles had moderate to mild (C73R/A66V) phenotypes, consistent with the expression of sufficient residual activity to produce adequate heme to avoid transfusion dependence. Similarly, patients with a single allele that expressed significant activity in E. coli might be expected to have milder phenotypes. However, the expressed residual activity must be assessed for its relative stability. For example, the patient with the L4F/V82F might be expected to be mild, since the V82F allele had -36% of expressed normal activity. However, when the V82F residual activity was incubated at 370C, the mutant enzyme proved unstable. Thus, heteroallelism for L4F and V82F was consistent with the moderately severe phenotype of this patient. The presence of residual activity with relatively normal stability of the expressed enzyme would be consistent with a milder phenotype. Further analysis of the URO-synthase genotypes of these and other CEP patients should further delineate the molecular heterogeneity underlying CEP and provide additional genotype/phenotype correlations.
